LOX NRAGE Protein Interaction Modulation for Skin Homeostasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective methods to modulate the interaction between LOX and NRAGE proteins, which are crucial for regulating cellular balance between proliferation, differentiation, and apoptosis, particularly in skin conditions affected by age, UV exposure, or pathological situations like psoriasis and cancer.
Innovation Solution
The use of specific substances that modulate the expression and activity of LOX and NRAGE proteins to restore their normal co-expression and interaction, thereby regulating cellular balance, involves identifying active principles that affect the mRNA expression and activity of these proteins, particularly in keratinocytes, using techniques like quantitative RT-PCR and yeast two-hybrid assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If substances are used to modulate LOX and NRAGE protein expression, then cellular homeostasis is restored and interaction between LOX and NRAGE is improved, but the complexity of identifying and characterizing active principles increases
Solution Approach 1:
The identification process is divided into distinct segments: (1) screening for substances that modulate LOX and/or NRAGE expression, (2) characterizing the mode of action (upregulation/downregulation), and (3) evaluating restoration of cellular homeostasis. This segmented approach manages complexity by breaking down the overall task into manageable stages with clear objectives at each step.
Solution Approach 2:
The patent uses quantitative RT-PCR as an intermediary tool to measure mRNA expression levels of LOX and NRAGE, and yeast two-hybrid assays as intermediaries to detect protein-protein interactions. These intermediary methods provide objective, quantifiable data that bridge the gap between substance application and homeostasis restoration, making the complex identification process more systematic and reliable.
2Measurement precision
If quantitative RT-PCR and yeast two-hybrid assays are used to identify active principles, then measurement precision of LOX and NRAGE expression and interaction is improved, but the time and resources required increase
Solution Approach 1:
The patent employs preliminary screening methods to identify candidate substances that modulate LOX and/or NRAGE expression before applying them to cell models. This preliminary action filters out non-active substances early, reducing the overall time required for comprehensive characterization while maintaining measurement precision for the most promising candidates.
Solution Approach 2:
The patent systematically varies parameters such as substance concentration, exposure time, and cell model conditions to optimize the balance between measurement precision and identification time. By adjusting these parameters, the methodology achieves accurate quantification of LOX and NRAGE expression and interaction without requiring excessive time or resources for each individual measurement.
Data Source
AI summary
The disclosed substance restores normal co-expression and interaction between the LOX and NRAGE proteins. Particularly, an effective amount of the substance that modulates the expression and/or activity of LOX of SEQ ID NO: 1 and/or that modulates the expression and/or activity of NRAGE of SEQ ID NO: 2, may be used for the manufacture of a composition for modulating the interaction between the LOX and NRAGE proteins to regulate the balance between the cellular phenomena of proliferation, differentiation and apoptosis, particularly in cases where the balance between these phenomena is disturbed, and especially in cases where the interaction between LOX and NRAGE is absent or altered. The invention makes it possible especially to treat and/or prevent skin ageing, lichen planus, graft-versus-host reaction (GVH), eczema, psoriasis and a cancer, particularly an epithelial cancer and more particularly a cutaneous epithelial cancer of basocellular or spinocellular type.